Wells Fargo Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $55
Tandem Diabetes Care: Positioned for Growth With FDA Approval of Control IQ+
Earnings Scheduled For February 26, 2025
CCORF Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $63
Tandem Diabetes Care (TNDM) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Express News | Tandem Diabetes Care Inc: Control-Iq+ Is Expected to Be Available for New and Existing Customers in United States in March 2025
Express News | Tandem Diabetes Care Announces FDA Clearance of Control-Iq+ Automated Insulin Delivery Technology for People With Type 2 Diabetes
Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People With Type 2 Diabetes
Tandem Raises USD 10M in Its Pre-seed Round to Revolutionize Pet Healthcare
Earnings Preview: TNDM to Report Financial Results Post-market on February 26
Beta Bionics Rated New Neutral at Baird on Valuation
Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?
Tandem Diabetes Care Announces Upcoming Conference Presentations
Home Healthcare Inflation Is Stubbornly High -- WSJ
FDA Advises Diabetes Device Users to Check Alert Settings
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Could Be 45% Below Their Intrinsic Value Estimate
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock?
Press Release: Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Bernstein Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $44